Pietro Napodano

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Renal Involvement in Primary Antiphospholipid Syndrome

Renato Alberto Sinico, Ilaria Cavazzana, Monica Nuzzo et al. · Clinical Journal of the American Society of Nephrology · 2010 · 90 citations

Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases

Antonella Radice, Federico Pieruzzi, Barbara Trezzi et al. · Journal of Nephrology · 2017 · 76 citations

Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects

Giuseppe Conte, Antonio Dal Canton, Massimo Sabbatini et al. · Kidney International · 1989 · 73 citations · Full text

Urology, Renal Function, Healthy Subjects +9